MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

Search

Grifols SA

Închisă

SectorFinanțe

8.408 0.17

Rezumat

Modificarea prețului

24h

Curent

Minim

8.344

Maxim

8.704

Indicatori cheie

By Trading Economics

Venit

17M

69M

Vânzări

183M

2B

P/E

Medie Sector

45.229

22.015

EPS

0.101

Marjă de profit

3.491

Angajați

23,833

EBITDA

57M

482M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+72.24% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

3.3B

6.8B

Deschiderea anterioară

8.24

Închiderea anterioară

8.408

Sentimentul știrilor

By Acuity

65%

35%

484 / 542 Clasament în Finance

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Grifols SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 apr. 2025, 17:19 UTC

Achiziții, Fuziuni, Preluări

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 apr. 2025, 13:02 UTC

Achiziții, Fuziuni, Preluări

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 apr. 2025, 10:13 UTC

Achiziții, Fuziuni, Preluări

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8 iul. 2024, 10:40 UTC

Achiziții, Fuziuni, Preluări

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8 iul. 2024, 09:13 UTC

Achiziții, Fuziuni, Preluări

Grifols Faces Delisting Bid From Founding Family and Brookfield

2 apr. 2025, 09:27 UTC

Acțiuni populare

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Comparație

Modificare preț

Grifols SA Așteptări

Obiectiv de preț

By TipRanks

72.24% sus

Prognoză pe 12 luni

Medie 14.02 EUR  72.24%

Maxim 19.05 EUR

Minim 11 EUR

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGrifols SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

8.152 / 8.574Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

484 / 542 Clasament în Finanțe

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.